<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33009077</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1531-7021</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in ophthalmology</Title>
          <ISOAbbreviation>Curr Opin Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Update on neuromyelitis optica spectrum disorder.</ArticleTitle>
        <Pagination>
          <StartPage>462</StartPage>
          <EndPage>468</EndPage>
          <MedlinePgn>462-468</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/ICU.0000000000000703</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Neuromyelitis optica spectrum disorder is an autoimmune disease that causes optic neuritis and transverse myelitis. Attacks can cause severe neurological damage leading to blindness and paralysis. Understanding of the immunopathogenesis of this disease has led to major breakthroughs in diagnosis and treatment. In the past 18 months, three successful phase 3 clinical trials have been published using targeted approaches to preventing relapses.</AbstractText>
          <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Updates in epidemiology, imaging, quality of life and treatment for acute relapse and prevention have been published in the past 18 months. Epidemiology studies are distinguishing patients based on their antigen specificity for aquaporin-4 and myelin oligodendrocyte glycoprotein, which are increasingly recognized as separate immunological conditions. Imaging by MRI and optical coherence tomography continue to be developed as tools to distinguish neuromyelitis optica spectrum disorders (NMOSD) from other diseases. This is especially relevant as the recent clinical trials showed differences in response between aquaporin-4 seropositive and seronegative patients. The three drugs that were tested for prevention of NMOSD relapses were eculizumab, inebilizumab, and satralizumab. All of the trials were worldwide, placebo-controlled, double-masked studies that demonstrated a clear benefit with each approach.</AbstractText>
          <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Recent research in NMOSD has resulted in improved diagnosis and approved treatments.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Holroyd</LastName>
            <ForeName>Kathryn B</ForeName>
            <Initials>KB</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Mass General Brigham Neurology Residency.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manzano</LastName>
            <ForeName>Giovanna S</ForeName>
            <Initials>GS</Initials>
            <AffiliationInfo>
              <Affiliation>Harvard Mass General Brigham Neurology Residency.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levy</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI130548</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Opin Ophthalmol</MedlineTA>
        <NlmUniqueID>9011108</NlmUniqueID>
        <ISSNLinking>1040-8738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009902" MajorTopicYN="N">Optic Neuritis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflicts of interest:</b> ML received consulting fees from Alexion, Viela Bio and Genentech/Roche/Chugai, Quest Diagnostics and UCB Pharmaceuticals. KH and GM have no financial interests to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33009077</ArticleId>
        <ArticleId IdType="mid">NIHMS1651373</ArticleId>
        <ArticleId IdType="pmc">PMC7771018</ArticleId>
        <ArticleId IdType="doi">10.1097/ICU.0000000000000703</ArticleId>
        <ArticleId IdType="pii">00055735-202011000-00003</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012;2012:460825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3272864</ArticleId>
            <ArticleId IdType="pubmed">22363840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17310032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeil MR, Liss JM, Tseng CH, Kent RD. Effects of speech rate on the absolute and relative timing of apraxic and conduction aphasic sentence production. Brain Lang. 1990;38(1):135–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2302543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019;27:412–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30530071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16717206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sepúlveda M, Aldea M, Escudero D, et al.
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2017:1352458517735191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28984163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papp V, Illes Z, Magyari M, et al.
Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology. 2018;91(24):e2265–e2275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6329324</ArticleId>
            <ArticleId IdType="pubmed">30413632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JE, Park SH, Han K, Kim HJ, Shin DW, Kim SM. Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. Mult Scler. 2019:1352458519888609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31749401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Cabre P, Weinshenker BG, et al.
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4988933</ArticleId>
            <ArticleId IdType="pubmed">26891082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houzen H, Kondo K, Niino M, et al.
Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology. 2017;89(19):1995–2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28986408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bukhari W, Prain KM, Waters P, et al.
Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88(8):632–638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28550069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holroyd K, Vogel A, Lynch K, et al.
Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries. Mult Scler Relat Disord. 2019;33:44–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31154260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eskandarieh S, Nedjat S, Azimi AR, Moghadasi AN, Sahraian MA. Neuromyelitis optica spectrum disorders in Iran. Mult Scler Relat Disord. 2017;18:209–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29141812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169–176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6454358</ArticleId>
            <ArticleId IdType="pubmed">30872305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek SH, Kim JS, Jang MJ, et al.
Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women In: J Neurol Neurosurg Psychiatry. Vol 89
England: 2018:1228–1230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6227799</ArticleId>
            <ArticleId IdType="pubmed">29371414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moghadasi AN. Environmental and genetic risk factors in the development of neuromyelitis optica In. Vol 15
Expert Review of Ophthalmology 2020:1–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang KY, Chetta J, Bains P, et al.
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. Br J Radiol. 2018;91(1086):20170690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6223278</ArticleId>
            <ArticleId IdType="pubmed">29388807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacciaguerra L, Meani A, Mesaros S, et al.
Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann Neurol. 2019;85(3):371–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30635936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ameli R, C RGG, Prieto JC, et al.
Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. J Neuroradiol. 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30981824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kab T, Steiner I, Fichman-Horn S. Neuromyelitis Optica with Lesions Involving the Optic Nerves, the Optic Chiasm, and the Optic Tracts In: Eur Neurol. Vol 80
Switzerland: 2018:333–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30897583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen T, You Y, Arunachalam S, et al.
Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmology. 2019;126(3):445–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30060979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan I, Hellmann MA, Benninger F, Stiebel-Kalish H, Steiner I. Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease. J Neuroimmunol. 2018;324:115–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30267996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vabanesi M, Pisa M, Guerrieri S, et al.
In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. Sci Rep. 2019;9(1):10371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6637174</ArticleId>
            <ArticleId IdType="pubmed">31316082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Qiu W, Zhang Y, et al.
A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder- optic neuritis and idiopathic optic neuritis. BMC Ophthalmol. 2018;18(1):247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6137880</ArticleId>
            <ArticleId IdType="pubmed">30217177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisa M, Ratti F, Vabanesi M, et al.
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. Mult Scler. 2019:1352458519861603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31392924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Mora DA, Flotats A, Fernandez A, Sizova M, Camacho V, Carrio I. Striking neurologic 18F-FDG PET/CT pattern in Devic's disease (neuromyelitis optica spectrum disorder). Eur J Nucl Med Mol Imaging. 2020;47(2):511–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31776629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Boscoe A, Caro J, Levy M. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. Int J MS Care. 2019;21(3):129–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6552992</ArticleId>
            <ArticleId IdType="pubmed">31191178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beekman J, Keisler A, Pedraza O, et al.
Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6624099</ArticleId>
            <ArticleId IdType="pubmed">31355316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asseyer S, Schmidt F, Chien C, et al.
Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2018;4(3):2055217318796684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6117869</ArticleId>
            <ArticleId IdType="pubmed">30186620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyun JW, Jang H, Yu J, et al.
Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. J Clin Neurol. 2020;16(1):124–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6974826</ArticleId>
            <ArticleId IdType="pubmed">31942768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Mossburg SE, Kim SH, et al.
Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019;28:64–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397677</ArticleId>
            <ArticleId IdType="pubmed">30554040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhang Q, Shi Z, et al.
Sexual dysfunction in patients with neuromyelitis optica spectrum disorder. J Neuroimmunol. 2020;338:577093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31726377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crnosija L, Krbot Skoric M, Andabaka M, et al.
Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. Mult Scler. 2019:1352458519837703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30887872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz J, Padmanabhan A, Aqui N, et al.
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3):149–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27322218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipphardt M, Muhlhausen J, Kitze B, et al.
Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J Clin Apher. 2019;34(4):381–391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30698295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ipe TS, Raval JS, Fernando LP, et al.
Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. J Clin Apher. 2020;35(1):25–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31705563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srisupa-Olan T, Siritho S, Kittisares K, Jitprapaikulsan J, Sathukitchai C, Prayoonwiwat N. Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2018;20:115–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29414283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori S, Kurimoto T, Ueda K, Nakamura M. Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. Jpn J Ophthalmol. 2018;62(4):525–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29802557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22(2):185–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4795457</ArticleId>
            <ArticleId IdType="pubmed">25921047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Songthammawat T, Srisupa-Olan T, Siritho S, et al.
A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2019;38:101506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31731214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chihara N, Aranami T, Sato W, et al.
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701–3706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3048150</ArticleId>
            <ArticleId IdType="pubmed">21321193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6636936</ArticleId>
            <ArticleId IdType="pubmed">31232925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sepulveda M, Delgado-Garcia G, Blanco Y, et al.
Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm. 2019;6(6).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6745725</ArticleId>
            <ArticleId IdType="pubmed">31471461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso YD, Ruocco HH, Dias RM, et al.
Late Onset of Neuromyelitis Optica Spectrum Disorders. Neurol Ther. 2019;8(2):477–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6858916</ArticleId>
            <ArticleId IdType="pubmed">31267407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Lin DY, Zeng D, et al.
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310–1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6487334</ArticleId>
            <ArticleId IdType="pubmed">30938427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunchok A, Malpas C, Nytrova P, et al.
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019;38:101868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31877445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee A, Ng J, Coleman J, Ospina JP, Mealy M, Levy M. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Disord. 2019;28:60–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397696</ArticleId>
            <ArticleId IdType="pubmed">30554039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragoso YD, Sousa NAC, Saad T, et al.
Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. J Child Neurol. 2019;34(9):487–490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31012355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Kessler RA, Rimler Z, et al.
Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5994702</ArticleId>
            <ArticleId IdType="pubmed">29892608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Garcia G, Chavez Z, Rivas-Alonso V, Corona T, Flores-Rivera J. Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica. Mult Scler Relat Disord. 2018;25:268–270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30149303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long Y, Liang J, Wu L, et al.
Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. Front Neurol. 2017;8:62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5328993</ArticleId>
            <ArticleId IdType="pubmed">28293214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnan M, Debeugny S, Mejdoubi M, Cabre P. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder. Mult Scler. 2019:1352458519834857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30843448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;41:102045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32179485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akaishi T, Takahashi T, Nakashima I, et al.
Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci. 2020;410:116671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31927341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Kim SH, Schmidt F, et al.
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018;24(13):1737–1742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5794637</ArticleId>
            <ArticleId IdType="pubmed">28857723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popiel M, Psujek M, Bartosik-Psujek H. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Mult Scler Relat Disord. 2018;26:204–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30268042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barros PO, Cassano T, Hygino J, et al.
Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4750605</ArticleId>
            <ArticleId IdType="pubmed">26472479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita T, Tateishi T, Isobe N, et al.
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013;8(4):e61835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3630114</ArticleId>
            <ArticleId IdType="pubmed">23637915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Shi F-D. Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): a multicenter, randomised, head-to-head comparison trial. In. The Lancet Neurology.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7935423</ArticleId>
            <ArticleId IdType="pubmed">32333897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahara M, Oeda T, Okada K, et al.
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32199095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kim Y, Kim G, et al.
Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment In: J Neurol Neurosurg Psychiatry. Vol 90
England: 2019:486–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29929977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lebrun C, Cohen M, Rosenthal-Allieri MA, et al.
Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. Neurol Ther. 2018;7(2):373–383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6283795</ArticleId>
            <ArticleId IdType="pubmed">29881979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcinno A, Marnetto F, Valentino P, et al.
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6148550</ArticleId>
            <ArticleId IdType="pubmed">30258855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munger KC, Samkoff LM. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy. Mult Scler Relat Disord. 2020;37:101442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32173005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miranda-Acuna J, Rivas-Rodriguez E, Levy M, et al.
Rituximab during pregnancy in neuromyelitis optica: A case report. Neurol Neuroimmunol Neuroinflamm. 2019;6(2):e542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6384016</ArticleId>
            <ArticleId IdType="pubmed">30800724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler. 2019;25(8):1150–1161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29761736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima M, Oji S, Tanaka S, et al.
Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Mult Scler Relat Disord. 2019;39:101907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31931404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burt RK, Balabanov R, Han X, et al.
Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732–e1741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6946475</ArticleId>
            <ArticleId IdType="pubmed">31578302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz Sand I, Fabian MT, Telford R, et al.
Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018;5(2):e441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6201737</ArticleId>
            <ArticleId IdType="pubmed">30426035</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
